Conventional Vaccines
Wacker Biotech has more than 20 years of experience as a CDMO for vaccines using microbial hosts. Our expertise extends to the process development and manufacturing of a variety of vaccine products, ranging from live, attenuated, inactivated and (conjugated) polysaccharide vaccines, to protein- and mRNA-based vaccines. EMA/FDA-approved production lines are available for this, with volumes of 250 L (single-use reactor) up to 1,500 L (stainless-steel fermenter).
Our production sites are home to state-of-the-art biosafety level 1 (Halle, Jena) and 2 (Amsterdam) facilities, as well as an explosion-proof room (Amsterdam) for manufacturing vaccine products under ICH and GMP quality guidelines. Our stainless-steel fermenter has a capacity of 1,500 L, and our single-use reactors can accommodate volumes of up to 250 L. Furthermore, at our site in Amsterdam, we operate a modern GMP fill-and-finish facility for aseptic filling operations of up to 20,000 vials (DIN 2R to 20R) per batch as well as bulk lyophilization of up to 65 L. Wacker Biotech has produced and released more than 650 GMP vaccine batches for clinical (phase I to III) and commercial applications. We provide efficient solutions for customer-specific process development and process transfer, complemented by tailored analytics for quality control.
- Polysaccharide vaccines
- Live, attenuated vaccines
- Conjugated vaccines
- Recombinant protein vaccines
- mRNA-based vaccines